Log In
Print
BCIQ
Print
Print this Print this
 

IRT102

  Manage Alerts
Collapse Summary General Information
Company TNI BioTech Inc.
DescriptionLymphocytes incubated with methionine enkephalin and low-dose naltrexone that are re-infused into a patient
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner

Hubei Qianjiang Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today